Clinical pipeline
Vidac Pharma's clinical pipeline in dermatology and oncology.
vidacpharma.comCrawled Nov 21, 2026
Vidac Pharma's clinical pipeline in dermatology and oncology.
Vidac Pharma is advancing a first-in-class portfolio in dermatology and oncology based on modulation of cancer cell metabolism. The Company’s programs span late
Vidac Pharma's cancer metabolism platform — targeting the Warburg effect and VDAC/HK2 interactions.
Vidac Pharma's therapeutic focus areas in dermatology and oncology.
In view of the exceptional safety found in the Phase 2B for AK, the Company was allowed to enter directly into a Phase 2 for CTCL. The Phase 2 was initiated in
VDA-1102 is an anti-neoplastic agent that utilizes a novel mechanism of action involving selective modulation of VDAC/HK2, a molecular system that is unique to
The page explains that cancer cells exhibit increased glucose uptake and metabolism, a process called glycolysis.
Selection supports the establishment of Eutopos Pharma and the Group's growth in Europe's biotech ecosystem. London, UK, 15 July 2026 – Vidac Pharma Holdings Plc. announces that its planned French affiliate, Eutopos Pharma, has been selected to join Quest for Health.
Vidac Pharma conference presentations, investor events, and scientific meetings.
London (UK) January 28th, 2025– Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmac
Media coverage and analyst reports on Vidac Pharma Holdings PLC.
Latest press releases and announcements from Vidac Pharma Holdings PLC.
Peer-reviewed scientific articles and conference posters related to Vidac Pharma's oncology pipeline and cancer metabolism platform.
Contact Vidac Pharma Holdings PLC.
Vidac Pharma is advancing first-in-class oncology and onco-dermatology therapies based on cancer metabolism.